Monte Rosa Therapeutics Inc

Monte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecular glue degrader (MGD) medicines for patients with serious diseases. MGDs are small molecule protein degraders with the potential to treat diseases that other modalities, including other degraders, cannot address. The company's proprietary QuEEN (Quantitative and Engineered Elimination of Neosubstrates) discovery engine combines AI-guided chemistry, diverse chemical libraries, structural biology, and proteomics to rationally design MGDs. Monte Rosa's pipeline spans autoimmune and inflammatory diseases and oncology, with three programs in the clinic: MRT-8102 (NEK7-directed MGD targeting NLRP3 inflammasome/IL-1-driven inflammatory diseases including cardiovascular disease, gout, and hidradenitis suppurativa), MRT-6160 (VAV1-directed MGD for immune-mediated conditions, being advanced by Novartis under a global exclusive license agreement), and MRT-2359 (GSPT1-directed MGD for metastatic castration-resistant prostate cancer). The company also has preclinical programs targeting cyclin E1 and CDK2 for solid tumors. Monte Rosa generates revenue through collaboration and license agreements with Roche and Novartis, with the Novartis partnership including up to $2.1 billion in potential milestones. Updated Aug 6, 2026